secwatch.observer — SEC 8-K summary
======================================

Issuer:     QUEST DIAGNOSTICS INC (DGX)
CIK:        0001022079
Form:       8-K
Filed at:   2022-03-02T23:59:59+00:00
Accession:  0001022079-22-000048
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quest Diagnostics director Dr. Helen I. Torley will not seek re-election; board size reduced to 9
--------------------------------------------------------------------------------

- Dr. Torley, President & CEO of Halozyme, chose not to stand for re-election at the May 18, 2022 annual meeting.
- Board reduced its size from 10 to 9 directors, effective at the annual meeting.
- Dr. Torley cited a desire to focus on board service for companies developing innovative medicines.
- No disagreement with the company was disclosed regarding her departure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022079/000102207922000048/0001022079-22-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022079/000102207922000048/dgx-20220224.htm
  HTML page:      https://secwatch.observer/filing/0001022079-22-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer